Saliva Bone Density Biomarkers Analyzed via Clinical Strips and ELISA
Mary Catherine Reynolds; Niping Wang, DMD PhD; Andrew Smith, MD PhD
Department of Periodontics and Preventative Sciences, School of Dentistry, University of Mississippi Medical Center
-Osteoporosis is a condition of decreased bone mineral density (BMD). Over 53 million people in the United States have osteoporosis. Osteoporosis risk factors include female sex, increased age, Caucasian or Asian decent, family history of osteoporosis, small body frames, etc.
-The ability to quickly and easily identify patients with osteoporosis is a newer topic in diagnostic medicine.
-The association between BMD and low osteocalcin level or high deoxypyridinoline (DPD) level in serum has been known.
-Osteocalcin is the most specific marker of osteoblast function and a reliable indicator of bone turnover. It is incorporated into the extracellular matrix of bone during deposition.
-DPD is the most specific marker of systemic osteoclast activity, as it is released into the circulation after resorption of bone matrix.
-In attempts to have a saliva test strip that aids as an early detector of bone loss and osteoporosis, this Phase II clinical study analyzed the association between bone density computer tomography (CT) scans and saliva osteocalcin and DPD levels, measured by enzyme-linked immunosorbent assay (ELISA) and clinical salivary test strips.